Lotus Reports October 2026 Revenue of NT$2,135 Million

Lotus Reports October 2026 Revenue of NT$2,135 Million

Taipei, Taiwan, 10 November 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for October 2026 of NT$2,135 million, representing a decrease of 22% YoY. The decrease mainly driven by prior year one-off shipping patterns in the of lenalidomide in the US. Lotus' year-to-date (YTD) October 2026 revenue reached NT$26,953 million, an increase of 59% compared to the same period last year, continued to be supported by Alvogen as well as strong performance in the B2B business.

For the first ten months ending October 2026, revenue from the US grew 116% YoY to NT$15,473 million for the period, representing c.57% of the total consolidated revenue, driven by the consolidation of Alvogen. Lotus’ Asia business remained stable with revenue of NT$9,404 million, representing c.35% of the Group’s total consolidated revenue. Lotus’ B2B business grew 174% YoY to NT$2,076 million, contributing c.8% of total consolidated revenue, supported by key product launches such as Nintedanib in Europe and North America as well as Enzalutamide in Brazil, Canada and South Korea.

*For B2B markets, “launch” refers to the initial product shipment to a partner; in-market launch timing is subject to local commercial arrangements.

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness

Media Inquiries

Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications

+886 2 2700 5908

investor@lotuspharm.com